42 research outputs found
Advanced decision making in sustainable city logistics projects : criteria and, risk identification and assessment
Les villes sont les lieux de la plus grande concentration d'activités sociales et économiques. La logistique est l'une des plus importants éléments de la durabilité et de l'économie d’une la ville. Pour la logistique urbaine, il est nécessaire de prendre en compte les caractéristiques de la ville et les objectifs de toutes les parties prenantes (expéditeurs, destinataires, transporteurs, prestataires de services logistiques, résidents, gouvernement de la ville). Les plans de logistique urbaine durable pourraient avoir un impact significatif sur la qualité de la vie en milieu urbain. L'évaluation d'initiatives de logistique de ville durable (SCLI) telles que les centres de distribution urbains, la tarification de la congestion, le délai de livraison et les restrictions d'accès est un problème complexe, car plusieurs critères et contraintes subjectifs et objectifs doivent être pris en compte. Les administrations municipales investissent dans des initiatives de logistique urbaine durable telles que les centres de distribution urbains, la tarification de la congestion, le calendrier de livraison et les restrictions d'accès afin d'améliorer les conditions de transport de marchandises dans les villes et de réduire leurs impacts négatifs sur les citoyens et leur environnement. Cependant, il y a toujours des risques dynamiques associés à la sélection. L’analyse des risques des initiatives de logistique urbaine est une tâche complexe en raison de la multiplicité des facteurs de risque et de leurs dépendances. Bien qu'il n'y ait pas beaucoup d'études sur les risques liés à la logistique urbaine, aucune attention n'a été portée à l'analyse des risques liés à la logistique urbaine en prenant en compte les dépendances entre les facteurs de risque et leurs critères. Considérer les dépendances entre les facteurs de risque pourrait conduire à une analyse plus précise des risques et augmenter le taux de réussite de la sélection des initiatives de logistique urbaine. Méthodes: pour résoudre ce problème, nous proposons un outil avancé d'aide à la décision appelé «cartescognitives floues» (FCM), capable de gérer les risques associés à des systèmes aussi complexes. La FCM représente avec précision le comportement de systèmes complexes et peut prendre en compte les incertitudes, les informations imprécises, les interactions entre les facteurs de risque, la rareté de l'information et les opinions de plusieurs décideurs. En outre, il pourrait être appliqué à différents problèmes de prise de décision liés aux initiatives de logistique de ville durable (SCLI). Par conséquent, l'outil proposé aiderait les praticiens à gérer les risques liés à la logistique urbaine d'une manière plus efficace et proactive et offrirait de meilleures solutions d'atténuation des risques. Dans les études précédentes, les méthodes de décision multicritères étaient principalement utilisées pour l'évaluation, la comparaison et la sélection d'initiatives logistiques de villes en fonction des effets obtenus ou prévus résultant de leur introduction dans divers environnements urbains. Afin d'évaluer l'adéquation des solutions conceptuelles aux exigences des différentes parties prenantes et conformément aux attributs spécifiques de l'environnement urbain, il convient de définir des solutions conceptuelles associant différentes initiatives de logistique urbaine en utilisant un processus artificiel; outils de renseignement, y compris la FCM.The cities are the places of the largest concentration of social activities and economic. Logistics is one of the most important for the sustainability and the economy of the city. Inselecting the city logistics concept, it is necessary to consider the characteristics of the city and the goals of all the stakeholders (shippers, receivers, carriers, logistics service providers, residents, city government). Sustainable city logistics (SCL) plans could significantly affect the quality of life in the urban environment. Evaluating sustainable city logistics initiatives (SCLI) such as urban distribution centres, congestion pricing, delivery timing and access restrictions is a complex problem since several subjective and objective criteria and constraints should be considered. Municipal administrations are investing in sustainable city logistics initiatives (SCLI) such as urban distribution centres, congestion pricing, delivery timing and access restrictions in order to improve the condition of goods transport in cities and reduce their negative impacts on citizens and their environment. However, there is always some dynamic risks associated that should be selected. Risk analysis of sustainable city logistics initiatives is a complex task due to consisting of many risk factors with dependencies among them. Although there are no lots of studies on sustainable city logistics risks, no attention has been paid to the risk analysis of sustainable city logistics by considering the dependencies among risk factors and their criteria. Considering the dependencies among risk factors could lead to more precise risks analysis and increase the success rate of selecting sustainable city logistics initiatives. Methods: To address this, we are proposing an advanced decision support tool called "Fuzzy Cognitive Maps" (FCM) which can deal with risks of such complicated systems. FCM represents the behaviour of complex systems accurately and is able to consider uncertainties, imprecise information, the interactions between risk factors, information scarcity, and several decision maker's opinions. In addition, it could be applied to different decision makings problems related to sustainable city logistics initiatives (SCLI). Therefore, the proposed tool would help practitioners to manage sustainable city logistics risks in a more effective and proactive way and offer better risk mitigation solutions. In previous studies, multi-criteriadecision-making methods are mainly used for the evaluation, comparison and selection of individual sustainable city logistics initiatives in relation to the achieved or planned effects resulting from their introduction in various urban environments. In order to assess the suitability of the conceptual solutions to the requirements of different stakeholders, and in accordance with the specific attributes of the urban environment, there is the definition of conceptual solutions that combine different sustainable city logistics initiatives by using an artificial; intelligence tools including FCM
Postharvest melatonin treatment reduces chilling injury and enhances antioxidant capacity of tomato fruit during cold storage
In this study, tomato fruit was treated with 50, 100 or 200 µM melatonin and then stored at 5°C for 28 days to investigate the effect of melatonin treatment on chilling injury, nutritional quality and changes in the antioxidant system. Tomato fruit developed chilling injury, manifested as surface pitting and irregular red color development during storage. These chilling injury symptoms, ion leakage and malondialdehyde content were significantly reduced, and proline and carotenoids contents were significantly increased by melatonin treatment. Meanwhile, melatonin substantially reduced O2- production rate and H2O2 content, which result from significantly higher activities of superoxide dismutase, catalase, and peroxidase than control during the storage. These results suggest that melatonin treatment can effectively enhance chilling tolerance and reduce chilling injury. The reduction in chilling injury by melatonin may be associated with enhanced enzymatic and non-enzymatic antioxidants, in favor of membrane integrity and thus low cellular and tissue damage
The driver landscape of sporadic chordoma.
Chordoma is a malignant, often incurable bone tumour showing notochordal differentiation. Here, we defined the somatic driver landscape of 104 cases of sporadic chordoma. We reveal somatic duplications of the notochordal transcription factor brachyury (T) in up to 27% of cases. These variants recapitulate the rearrangement architecture of the pathogenic germline duplications of T that underlie familial chordoma. In addition, we find potentially clinically actionable PI3K signalling mutations in 16% of cases. Intriguingly, one of the most frequently altered genes, mutated exclusively by inactivating mutation, was LYST (10%), which may represent a novel cancer gene in chordoma.Chordoma is a rare often incurable malignant bone tumour. Here, the authors investigate driver mutations of sporadic chordoma in 104 cases, revealing duplications in notochordal transcription factor brachyury (T), PI3K signalling mutations, and mutations in LYST, a potential novel cancer gene in chordoma
Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the Global Burden of Disease Study 2019
Background: Updated data on chronic respiratory diseases (CRDs) are vital in their prevention, control, and treatment in the path to achieving the third UN Sustainable Development Goals (SDGs), a one-third reduction in premature mortality from non-communicable diseases by 2030. We provided global, regional, and national estimates of the burden of CRDs and their attributable risks from 1990 to 2019. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we estimated mortality, years lived with disability, years of life lost, disability-adjusted life years (DALYs), prevalence, and incidence of CRDs, i.e. chronic obstructive pulmonary disease (COPD), asthma, pneumoconiosis, interstitial lung disease and pulmonary sarcoidosis, and other CRDs, from 1990 to 2019 by sex, age, region, and Socio-demographic Index (SDI) in 204 countries and territories. Deaths and DALYs from CRDs attributable to each risk factor were estimated according to relative risks, risk exposure, and the theoretical minimum risk exposure level input. Findings: In 2019, CRDs were the third leading cause of death responsible for 4.0 million deaths (95% uncertainty interval 3.6–4.3) with a prevalence of 454.6 million cases (417.4–499.1) globally. While the total deaths and prevalence of CRDs have increased by 28.5% and 39.8%, the age-standardised rates have dropped by 41.7% and 16.9% from 1990 to 2019, respectively. COPD, with 212.3 million (200.4–225.1) prevalent cases, was the primary cause of deaths from CRDs, accounting for 3.3 million (2.9–3.6) deaths. With 262.4 million (224.1–309.5) prevalent cases, asthma had the highest prevalence among CRDs. The age-standardised rates of all burden measures of COPD, asthma, and pneumoconiosis have reduced globally from 1990 to 2019. Nevertheless, the age-standardised rates of incidence and prevalence of interstitial lung disease and pulmonary sarcoidosis have increased throughout this period. Low- and low-middle SDI countries had the highest age-standardised death and DALYs rates while the high SDI quintile had the highest prevalence rate of CRDs. The highest deaths and DALYs from CRDs were attributed to smoking globally, followed by air pollution and occupational risks. Non-optimal temperature and high body-mass index were additional risk factors for COPD and asthma, respectively. Interpretation: Albeit the age-standardised prevalence, death, and DALYs rates of CRDs have decreased, they still cause a substantial burden and deaths worldwide. The high death and DALYs rates in low and low-middle SDI countries highlights the urgent need for improved preventive, diagnostic, and therapeutic measures. Global strategies for tobacco control, enhancing air quality, reducing occupational hazards, and fostering clean cooking fuels are crucial steps in reducing the burden of CRDs, especially in low- and lower-middle income countries
The global burden of cancer attributable to risk factors, 2010-19 : a systematic analysis for the Global Burden of Disease Study 2019
Background Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Findings Globally, in 2019, the risk factors included in this analysis accounted for 4.45 million (95% uncertainty interval 4.01-4.94) deaths and 105 million (95.0-116) DALYs for both sexes combined, representing 44.4% (41.3-48.4) of all cancer deaths and 42.0% (39.1-45.6) of all DALYs. There were 2.88 million (2.60-3.18) risk-attributable cancer deaths in males (50.6% [47.8-54.1] of all male cancer deaths) and 1.58 million (1.36-1.84) risk-attributable cancer deaths in females (36.3% [32.5-41.3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20.4% (12.6-28.4) and DALYs by 16.8% (8.8-25.0), with the greatest percentage increase in metabolic risks (34.7% [27.9-42.8] and 33.3% [25.8-42.0]). Interpretation The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe
National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019
An updated exploration of the burden of thyroid cancer across a country is always required for making correct decisions. The objective of this study is to present the thyroid cancer burden and attributed burden to the high Body Mass Index (BMI) in Iran at national and sub-national levels from 1990 to 2019. The data was obtained from the GBD 2019 study estimates. To explain the pattern of changes in incidence from 1990 to 2019, decomposition analysis was conducted. Besides, the attribution of high BMI in the thyroid cancer DALYs and deaths were obtained. The age-standardized incidence rate of thyroid cancer was 1.57 (95% UI: 1.33–1.86) in 1990 and increased 131% (53–191) until 2019. The age-standardized prevalence rate of thyroid cancer was 30.19 (18.75–34.55) in 2019 which increased 164% (77–246) from 11.44 (9.38–13.85) in 1990. In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.49 (0.36–0.53), and 13.16 (8.93–14.62), respectively. These numbers also increased since 1990. The DALYs and deaths attributable to high BMI was 1.91 (0.95–3.11) and 0.07 (0.04–0.11), respectively. The thyroid cancer burden and high BMI attributed burden has increased from 1990 to 2019 in Iran. This study and similar studies’ results can be used for accurate resource allocation for efficient management and all potential risks’ modification for thyroid cancer with a cost-conscious view
Burden of tracheal, bronchus, and lung cancer in North Africa and Middle East countries, 1990 to 2019: Results from the GBD study 2019
ObjectiveTo provide estimates on the regional and national burden of tracheal, bronchus, and lung (TBL) cancer and its attributable risk factors from 1990 to 2019 in the North Africa and Middle East (NAME) region.Methods and materialsThe Global Burden of Disease (GBD) 2019 data were used. Disability-adjusted life years (DALYs), death, incidence, and prevalence rates were categorized by sex and age groups in the NAME region, in 21 countries, from 1990 to 2019. Decomposition analysis was performed to calculate the proportion of responsible factors in the emergence of new cases. Data are presented as point estimates with their 95% uncertainty intervals (UIs).ResultsIn the NAME region, TBL cancer caused 15,396 and 57,114 deaths in women and men, respectively, in 2019. The age-standardized incidence rate (ASIR) increased by 0.7% (95% UI -20.6 to 24.1) and reached 16.8 per 100,000 (14.9 to 19.0) in 2019. All the age-standardized indices had a decreasing trend in men and an increasing trend in women from 1990 to 2019. Turkey (34.9 per 100,000 [27.6 to 43.5]) and Sudan (8.0 per 100,000 [5.2 to 12.5]) had the highest and lowest age-standardized prevalence rates (ASPRs) in 2019, respectively. The highest and lowest absolute slopes of change in ASPR, from 1990 to 2019, were seen in Bahrain (-50.0% (-63.6 to -31.7)) and the United Arab Emirates (-1.2% (-34.1 to 53.8)), respectively. The number of deaths attributable to risk factors was 58,816 (51,709 to 67,323) in 2019 and increased by 136.5%. Decomposition analysis showed that population growth and age structure change positively contributed to new incident cases. More than 80% of DALYs could be decreased by controlling risk factors, particularly tobacco use.ConclusionThe incidence, prevalence, and DALY rates of TBL cancer increased, and the death rate remained unchanged from 1990 to 2019. All the indices and contribution of risk factors decreased in men but increased in women. Tobacco is still the leading risk factor. Early diagnosis and tobacco cessation policies should be improved
Recommended from our members
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation
Characterization of epithelioid sarcoma using massively parallel DNA and RNA sequencing and in vitro models
Epithelioid sarcoma is a soft tissue tumor with an unusual predilection for the distal extremities in young adults. Despite wide-margin resections the 10-year survival is in the range of 50%. The biology of epithelioid sarcoma remains incompletely understood, but one key feature is the loss of SMARCB1. We use whole genome sequencing of five cases of epithelioid sarcoma matched to normal germline DNA, looking for mutations other than SMARCB1. These index cases are supplemented with three additional tumors and three cell lines that undergo whole transcriptome sequencing and are analyzed for somatic point mutations, copy number changes, translocations, and expression patterns. Unlike the situation in other SMARCB1 inactivated tumors, we find a complex genome with a relatively high mutational burden. However, aberrations of SMARCB1 remain the only consistent mutation. Some cases do not show biallelic DNA-level inactivation of this gene which leads us to examine other possible second-hit silencing mechanisms. With the significance attributed to SMARCB1 loss in the genomic landscape of epithelioid sarcoma, we explore two approaches, namely EZH2 and SMARCA4 inhibitions, to specifically exploit this abnormality and suggest novel therapeutic options.Medicine, Faculty ofGraduat